Compare HST & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HST | DVA |
|---|---|---|
| Founded | 1927 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 8.4B |
| IPO Year | N/A | 1995 |
| Metric | HST | DVA |
|---|---|---|
| Price | $18.36 | $121.50 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 4 |
| Target Price | $18.65 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 7.1M | 972.4K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | 3.27 | ★ 5.63 |
| EPS | 1.06 | ★ 9.76 |
| Revenue | $5,950,000,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $6.31 | $6.50 |
| Revenue Next Year | $1.80 | $2.97 |
| P/E Ratio | $17.35 | ★ $12.43 |
| Revenue Growth | ★ 6.44 | 5.14 |
| 52 Week Low | $12.22 | $113.97 |
| 52 Week High | $19.03 | $179.60 |
| Indicator | HST | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 64.76 | 54.23 |
| Support Level | $17.04 | $115.91 |
| Resistance Level | $17.69 | $122.61 |
| Average True Range (ATR) | 0.37 | 2.30 |
| MACD | 0.06 | 0.54 |
| Stochastic Oscillator | 89.42 | 83.43 |
Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.